|
|
|
Market Research Report
Cancer Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics
|
Cancer Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics published by Insight Pharma Reports in November, 2006. This report consists of 212 pages and the price starts from US $ 2750.
Abstract
Cancer continues to pose a major health burden worldwide. Prevailing therapies
are extremely limited in terms of safety, tolerability, and efficacy.
Meanwhile, the morbidity and mortality associated with cancer is fueling
interest in novel therapeutic approaches. Foremost among these are therapies
that enhance the ability of the body' s own immune system to fight and destroy
abnormal cancer cells. Anticancer vaccines and immune modulators, working in
concert and as monotherapy, stole the show at ASCO last June, suggesting that
after years of failure in the clinic their time has come. Cancer
Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics ,
a new CHA Advances report, surveys and assesses recent developments in this
highly promising avenue of cancer therapy.
Numerous biopharmaceutical companies are working to develop approaches that
harness the body' s own immune system to fight cancer. Several monoclonal
antibodies have already reached the market. This approach is sometimes
referred to as passive immunotherapy. Our study focuses on active
immunotherapies and vaccines that enhance the ability of the patient' s own
immune system to fight cancer.
Cancer Immunotherapies and Vaccines begins by reviewing the
pathophysiology, epidemiology, diagnosis, and current treatment options of
eight major cancers targeted by companies developing immune modulating drugs
and vaccines:
- breast cancer
- melanoma
- colorectal cancer
- pancreatic cancer
- lung cancer
- prostate cancer
- lymphoma
- renal cancer
While no active cancer immunotherapies (specifically targeted to a type of
cancer) have reached the market, the most advanced example is Dendreon' s
Provenge. Dendreon is submitting a rolling BLA (Biologics License
Application) to the FDA for Provenge, for treatment of advanced
hormone-refractory prostate cancer. Clinical trial data supporting this
BLA, and available data on other immunotherapies and vaccines, are
assessed in the report.
Cancer Immunotherapies and Vaccines also provides:
- An explanation of R&D challenges in the development of cancer
immunotherapies and vaccines
- The various technical approaches being used to develop active cancer
immunotherapies and vaccines
- The many emerging immune-based therapies that are currently being
evaluated in clinical trials for these eight cancers
- Interviews with six senior executives from leading companies in the field
of cancer immunotherapies and vaccines who discuss the progress, the
challenges and hurdles, faced by researchers
- Pipeline projects of over 35 companies, including discontinued projects
- Thirteen SWOT charts (strengths, weaknesses, opportunities, threats)
comparing the most promising immunotherapies and vaccines with standard
therapy in 6 major cancers
Table of Contents
CHAPTER 1
INTRODUCTION
- 1.1 Cancer
- 1.2 The Immune System
- 1.3 Cancer Therapy and the Immune System: Focus of the Report
CHAPTER 2
REVIEW OF MAJOR CANCERS TARGETED BY IMMUNOTHERAPIES AND VACCINES
- 2.1 Breast Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.2 Colorectal Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.3 Lung Cancer
- Pathology
- Non-Small-Cell Lung Cancer
- Small-Cell Lung Cancer
- Epidemiology
- Diagnosis
- 2.4 Lymphoma
- Pathology of Non-Hodgkin' s Lymphoma
- Epidemiology of Lymphoma
- Diagnosis of Non-Hodgkin' s Lymphoma
- 2.5 Melanoma
- Pathology
- Epidemiology
- Diagnosis
- 2.6 Pancreatic Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.7 Prostate Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.8 Renal Cancer
- Pathology
- Epidemiology
- Diagnosis
- 2.9 R&D Challenges in the Development of Cancer Immunotherapies and
Vaccines
CHAPTER 3
CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
- 3.1 Breast Cancer
- Chemotherapy
- Hormone Therapy
- Targeted Therapy: Herceptin
- 3.2 Colorectal Cancer
- Chemotherapy
- Targeted Therapy: Monoclonal Antibodies
- 3.3 Lung Cancer
- Chemotherapy (Non-Small-Cell Lung Cancer)
- Targeted Therapy: Kinase Inhibitors (Non-Small-Cell Lung Cancer)
- Photodynamic Therapy (Non-Small-Cell Lung Cancer)
- Chemotherapy (Small-Cell Lung Cancer)
- 3.4 Lymphoma
- Chemotherapy
- Monoclonal Antibodies
- Other Immuno-Based Therapies
- 3.5 Melanoma
- Interferon
- Interleukin 2
- Chemotherapy
- 3.6 Pancreatic Cancer
- Chemotherapy
- Targeted Therapy: Inhibition of Epidermal Growth Factor Receptor
Tyrosine Kinase
- 3.7 Prostate Cancer
- Luteinizing Hormone-Releasing Hormone Agonists
- Anti-androgens
- Chemotherapy
- 3.8 Renal Cancer
- Interferon
- Interleukin-2
- Targeted Therapy: Kinase Inhibitors
CHAPTER 4
CANCER IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT
- 4.1 New Approaches
- Non-Specific Active Immunotherapy (Immune Modulating Agents)
- Antigen Immunotherapies/Vaccines (Allogeneic)
- Autologous Antigen Immunotherapies/Vaccines
- Allogeneic Whole Tumor Cell Immunotherapies/Vaccines
- Autologous Whole Tumor Cell Immunotherapies/Vaccines
- Dendritic Cell Immunotherapies/Vaccines
- DNA and Viral Vector Vaccines
- 4.2 Setbacks
- 4.3 Breast Cancer
- Celldex Therapeutics
- GlaxoSmithKline
- Introgen Therapeutics
- Oxford BioMedica
- 4.4 Colorectal Cancer
- Celldex Therapeutics
- GenVec
- IDM Pharma
- Intracel
- Oxford BioMedica
- 4.5 Lung Cancer
- Active Biotech
- AVAX Technologies
- GlaxoSmithKline
- IDM Pharma
- Introgen Therapeutics
- Merck KGaA and Biomira
- NovaRx
- Pfizer and Coley Pharmaceutical
- Pharmexa
- Transgene
- 4.6 Lymphoma
- Biovest International
- Favrille
- Genitope
- Transgene
- 4.7 Melanoma
- Antigenics
- AVAX Technologies
- BioVex
- GenVec
- GlaxoSmithKline
- IDM Pharma
- Medarex and Bristol-Myers Squibb
- Merck KGaA
- Oxxon Therapeutics
- Pfizer
- Progenics Pharmaceuticals
- Vical
- 4.8 Pancreatic Cancer
- Celldex Therapeutics
- Cell Genesys
- GenVec
- GlobeImmune
- Lorus Therapeutics
- Pharmexa
- Receptor BioLogix
- 4.9 Prostate Cancer
- Cell Genesys
- Dendreon
- Northwest Biotherapeutics
- Oxford BioMedica
- 4.10 Renal Cancer
- Active Biotech
- Antigenics
- Argos Therapeutics
- Idera Pharmaceuticals
- Oxford BioMedica
CHAPTER 5.0
EXPERT INTERVIEWS - A VIRTUAL ROUNDTABLE
- Roman M. Chicz, PhD, Senior Vice President, Research and Development
- C. Richter King, PhD, Senior Vice President of Research
- Arthur M. Krieg, MD, Senior Vice President, Research and Development, and
Chief Scientific Officer
- Coley Pharmaceutical Group
- Christopher Nicodemus, MD, Senior Vice President, Research and Development
- Charles A. Nicolette, PhD, Vice President, Research and Development
- Peter K. Working, PhD, Senior Vice President, Research and Development
CHAPTER 6
COMPANY DIRECTORY WITH WEB ADDRESSES
References
Index
|
 |
